Showing papers by "Fabio A.B. Schutz published in 2010"
TL;DR: Treatment with VEGFR TKIs sunitinib and sorafenib is associated with a significant increase in the risk of ATEs, and random-effects or fixed-effects models based on the heterogeneity of included studies were used.
Abstract: Purpose Sunitinib and sorafenib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) used in a vast range of cancers. Arterial thromboembolic events (ATE) have been described with these agents, although the overall risk remains unclear. We did a systematic review and meta-analysis to determine the incidence and the relative risk (RR) associated with the use of sunitinib and sorafenib.
383 citations
TL;DR: A scoring system that classifies patients with platinum-refractory disease on second-line chemotherapy into four risk groups with different outcome is developed and similar to the first-line setting, the presence of visceral metastases and poor PS predict a worse prognosis.
Abstract: Purpose The present study sought to identify pretreatment prognostic factors for overall survival (OS) in patients with metastatic transitional cell carcinoma of the urothelial tract (TCCU) who experienced treatment failure with the first-line, platinum-based regimen included in the phase III vinflunine trial. Patients and Methods In total, 370 patients with platinum-refractory TCCU were included in this analysis. Potential prognostic factors were recorded prospectively. Univariate analysis was used to identify clinical and laboratory factors that significantly impact survival. Multivariate analysis was used to identify independent prognostic factors, and bootstrap analysis was performed for internal validation, forming a prognostic model. External validation was performed on the phase II vinflunine study CA183001. Results Multivariate analysis and the internal validation identified Eastern Cooperative Oncology Group performance status (PS) more than 0, hemoglobin level less than 10 g/dL, and the presence...
324 citations
TL;DR: This review discusses neoadjuvant and adjuvant therapies in prostate cancer, including hormonal therapy, chemotherapy, and postoperative radiotherapy.
13 citations
TL;DR: A humanized monoclonal antibody targeting the vascular endothelial growth factor (VEGF) is a therapeutic agent used in a variety of neoplasms and has shown promising results in animals and humans.
Abstract: 4609 Background: Bevacizumab (BEV), a humanized monoclonal antibody targeting the vascular endothelial growth factor (VEGF), is a therapeutic agent used in a variety of neoplasms. Arterial thromobo...
3 citations
TL;DR: Pre-clinical evidence suggests that VEGF plays a role in the homeostasis of endothelial cells, and targeted therapies have shown to be active in several malignancies.
Abstract: 4602 Background: Vascular endothelial growth factor (VEGF)-targeted therapies have shown to be active in several malignancies. Pre-clinical evidence suggests that VEGF plays a role in the homeostas...
2 citations
TL;DR: This data indicates that Vascular endothelial growth factor-targeted therapy has become a standard for the treatment of patients with metastatic renal cell cancer (mRCC) and may be applicable to other types of cancer.
Abstract: 4526 Background: Vascular endothelial growth factor (VEGF)-targeted therapy has become a standard for the treatment of patients (pts) with metastatic renal cell cancer (mRCC). Since these therapies...
1 citations
[...]
TL;DR: The results suggest that there is no difference in incidence of ATEs between patients receiving treatment of short or long duration, and the association between median treatment duration of the placebo group and incidence of AtEs with three trials found no significant association.
Abstract: arm. The incidence of ATEs was 1.0% (95% CI, 0.7 to 1.5%) for trials withtreatmentdurationsof3monthsorless,and1.5%(95%CI,1.2to 1.9%) for trials with treatment durations of more than 3 months. Similarly, the incidence of ATEs for trials with median treatment durationsof6monthsorlesswas1.9%(95%CI,1.0to3.7%),andfor trials longer than 6 months, 1.3% (95% CI, 1.0 to 1.6%). The differences failed to reach statistical significance for both cutoffs (P .276 and 0.281, respectively). These results suggest that there is no difference in incidence of ATEs between patients receiving treatment of short or long duration. Similarly, we examined the association between median treatment duration of the placebo group and incidence of ATEs with three trials, and found no significant association (P .426), suggesting that increasing the observation time by 1 month does not affect incidence of ATEs among placebo groups, either. In reference to the study by Nalluri et al, 2 we understand that patients with cancer are predisposed to have venous thrombotic events, and with additional follow-up on one treatment arm, more venous thrombotic events could potentially be recorded; however, this does not necessarily apply to arterial thrombosis. Our observation is also supported by several preclinical studies in which inhibiting vascular endothelial growth factor signaling was shown to lead to prothrombotic events, such as disruption of the regenerative capacity of endothelial cells, decrease in nitric oxide production, and induction of platelet aggregation. 3,4